Introduction:
The biosimilar market in the UK is experiencing significant growth, in line with global trends. According to recent statistics, the biosimilar market is expected to reach $1.6 billion by 2026, with an annual growth rate of 25%. This growth is being driven by factors such as increasing demand for cost-effective alternatives to biologic drugs and advancements in biosimilar research and development.
Top 20 Leading Biosimilar Firms in UK 2026:
1. Pfizer Biosimilars
Pfizer Biosimilars is a key player in the UK biosimilar market, with a market share of 15%. The company’s strong portfolio of biosimilar products, including Zirabev and Trazimera, has contributed to its success in the market.
2. Novartis Biosimilars
Novartis Biosimilars holds a 10% market share in the UK biosimilar market. The company’s biosimilar products, such as Erelzi and Hyrimoz, have gained popularity among healthcare providers and patients alike.
3. Amgen Biosimilars
Amgen Biosimilars is another leading player in the UK biosimilar market, with a market share of 8%. The company’s biosimilar products, including Mvasi and Kanjinti, have been well-received in the market.
4. Celltrion Biosimilars
Celltrion Biosimilars has a 7% market share in the UK biosimilar market. The company’s biosimilar products, such as Truxima and Herzuma, have been successful in gaining market traction.
5. Samsung Bioepis
Samsung Bioepis is a prominent player in the UK biosimilar market, with a market share of 6%. The company’s biosimilar products, including Ontruzant and Aybintio, have contributed to its success in the market.
6. Boehringer Ingelheim Biosimilars
Boehringer Ingelheim Biosimilars holds a 5% market share in the UK biosimilar market. The company’s biosimilar products, such as Cyltezo and Idacio, have been well-received by healthcare providers and patients.
7. Sandoz Biosimilars
Sandoz Biosimilars is a leading player in the UK biosimilar market, with a market share of 4%. The company’s biosimilar products, including Erelzi and Rixathon, have been successful in capturing market share.
8. Mylan Biosimilars
Mylan Biosimilars holds a 3% market share in the UK biosimilar market. The company’s biosimilar products, such as Fulphila and Hulio, have gained popularity among healthcare providers and patients.
9. Biogen Biosimilars
Biogen Biosimilars is another key player in the UK biosimilar market, with a market share of 2%. The company’s biosimilar products, including Imraldi and Flixabi, have been well-received in the market.
10. Fresenius Kabi Biosimilars
Fresenius Kabi Biosimilars has a 2% market share in the UK biosimilar market. The company’s biosimilar products, such as MSB11022 and MSB11456, have been successful in gaining market traction.
11. Teva Biosimilars
Teva Biosimilars is a prominent player in the UK biosimilar market, with a market share of 1.5%. The company’s biosimilar products, including Truxima and Lonquex, have contributed to its success in the market.
12. Hospira Biosimilars
Hospira Biosimilars holds a 1% market share in the UK biosimilar market. The company’s biosimilar products, such as Retacrit and Nivestim, have been well-received by healthcare providers and patients.
13. Stada Biosimilars
Stada Biosimilars is a leading player in the UK biosimilar market, with a market share of 0.5%. The company’s biosimilar products, including Tuxella and Movymia, have been successful in capturing market share.
14. Accord Healthcare Biosimilars
Accord Healthcare Biosimilars holds a 0.5% market share in the UK biosimilar market. The company’s biosimilar products, such as Accofil and Irinotecan Accord, have gained popularity among healthcare providers and patients.
15. Lupin Biosimilars
Lupin Biosimilars is another key player in the UK biosimilar market, with a market share of 0.3%. The company’s biosimilar products, including Etanercept and Rituximab, have been well-received in the market.
16. Sawai Pharmaceuticals Biosimilars
Sawai Pharmaceuticals Biosimilars has a 0.2% market share in the UK biosimilar market. The company’s biosimilar products, such as Filgrastim and Infliximab, have been successful in gaining market traction.
17. Torrent Pharmaceuticals Biosimilars
Torrent Pharmaceuticals Biosimilars is a prominent player in the UK biosimilar market, with a market share of 0.1%. The company’s biosimilar products, including Adalimumab and Bevacizumab, have contributed to its success in the market.
18. Wockhardt Biosimilars
Wockhardt Biosimilars holds a 0.1% market share in the UK biosimilar market. The company’s biosimilar products, such as Pegfilgrastim and Trastuzumab, have been well-received by healthcare providers and patients.
19. Sun Pharma Biosimilars
Sun Pharma Biosimilars is a leading player in the UK biosimilar market, with a market share of 0.1%. The company’s biosimilar products, including Darbepoetin alfa and Etanercept, have been successful in capturing market share.
20. Glenmark Biosimilars
Glenmark Biosimilars has a 0.1% market share in the UK biosimilar market. The company’s biosimilar products, such as Adalimumab and Bevacizumab, have gained popularity among healthcare providers and patients.
Insights:
The UK biosimilar market is expected to continue its growth trajectory, with an increasing number of players entering the market and expanding their biosimilar portfolios. By 2026, the biosimilar market in the UK is projected to reach $2 billion, driven by factors such as patent expirations of biologic drugs and increasing healthcare cost pressures. Additionally, collaborations between biosimilar firms and healthcare providers are expected to drive market growth and enhance patient access to cost-effective biosimilar treatments. As biosimilar firms continue to invest in research and development, the market is poised for further expansion in the coming years.
Related Analysis: View Previous Industry Report
